Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury
Despite the enormous advances made in the field of oncology, no solution to the side effect of nephrotoxicity caused by cisplatin used as an antineoplastic agent for approximately 40 years has yet been discovered. This study investigated the effects of cisplatin on the kidney, the damage mechanism involved, and the potential capacity of agents such as amifostine, curcumin, and melatonin to elicit a future therapeutic protocol in cisplatin-induced nephrotoxicity at the ultrastructural and molecular levels. Our study consisted of five groups: control (saline solution only; group 1), cisplatin (cisplatin only; group 2), cisplatin + amifostine (group 3), cisplatin + curcumin (group 4), and cisplatin + melatonin (group 5). Rats in all groups except the control group were administered a single intraperitoneal dose of 7.5 mg/kg cisplatin. All animals were sacrificed under anesthesia on the sixth day after cisplatin administration. Cisplatin increased serum urea and serum creatinine levels and caused an increase in tubular necrosis scores (TNS), HPS, NF-κB/p65, 8-OHdG, and caspase-3 expressions (p < 0.05). Additionally, we observed basal membrane thickening in glomerules, intense electron deposition in the subendothelial region, and atypical folds in podocyte pedicels. Amifostine, curcumin, and melatonin reduced the increases in serum urea and serum creatinine levels following cisplatin administration and reduced the levels of TNS, HPS, NF-κB/p65, 8-OHdG, and caspase-3 expressions (p < 0.05). ROS-scavenging antioxidants may be a promising means of preventing acute kidney disease in patients using cisplatin in the treatment of malignant tumors.
KeywordsAmifostine Cisplatin Curcumin Melatonin Nephrotoxicity
TM and FM conceived and designed the research. TM conducted the experiments. AY contributed new reagents or analytical tools. TM, FM, AY, AT, and LT analyzed the data. TM, FM, and AT wrote the manuscript. All authors read and approved the manuscript.
This work was supported by the Scientific Research Projects Unit of Recep Tayyip Erdogan University [TSA-2016-652, 2016].
Compliance with ethical standards
The study was approved by the Institutional Ethics committee and observed the ethical principles of the Declaration of Helsinki.
Conflict of interest
The authors declare that they have no conflicts of interest.
- Chen M-F, Yang C-M, Su C-M, Hu M-L (2014) Vitamin C protects against cisplatin-induced nephrotoxicity and damage without reducing its effectiveness in C57BL/6 mice xenografted with Lewis lung carcinoma. Nutr Cancer 66:1085–1091. https://doi.org/10.1080/01635581.2014.948211 CrossRefPubMedGoogle Scholar
- Galgamuwa R, Hardy K, Dahlstrom JE, Blackburn AC, Wium E, Rooke M, Cappello JY, Tummala P, Patel HR, Chuah A, Tian L, McMorrow L, Board PG, Theodoratos A (2016) Dichloroacetate prevents cisplatin-induced nephrotoxicity without compromising cisplatin anticancer properties. J Am Soc Nephrol 27:3331–3344. https://doi.org/10.1681/ASN.2015070827 CrossRefPubMedPubMedCentralGoogle Scholar
- Ghaznavi H, Mehrzadi S, Dormanesh B, Tabatabaei SMTH, Vahedi H, Hosseinzadeh A, Pazoki-Toroudi HR, Rashidian A (2016) Comparison of the protective effects of melatonin and silymarin against gentamicin-induced nephrotoxicity in rats. J Evid Based Complementary Altern Med 21:49–55. https://doi.org/10.1177/2156587215621672 CrossRefGoogle Scholar
- Huang YC, Tsai MS, Hsieh PC, Shih JH, Wang TS, Wang YC, Lin TH, Wang SH (2017) Galangin ameliorates cisplatin-induced nephrotoxicity by attenuating oxidative stress, inflammation and cell death in mice through inhibition of ERK and NF-kappaB signaling. Toxicol Appl Pharmacol 329:128–139. https://doi.org/10.1016/j.taap.2017.05.034 CrossRefPubMedGoogle Scholar
- Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW (2015) TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 33:1902–1909. https://doi.org/10.1200/JCO.2014.57.6660 CrossRefPubMedPubMedCentralGoogle Scholar
- Kawahara A, Azuma K, Hattori S, Nakashima K, Basaki Y, Akiba J, Takamori S, Aizawa H, Yanagawa T, Izumi H, Kohno K, Kono S, Kage M, Kuwano M, Ono M (2010) The close correlation between 8-hydroxy-2′-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer. Hum Pathol 41:951–959. https://doi.org/10.1016/j.humpath.2009.12.007 CrossRefPubMedGoogle Scholar
- Ma Z-N, Liu Z, Wang Z, Ren S, Tang S, Wang YP, Xiao SY, Chen C, Li W (2017) Supplementation of American ginseng berry extract mitigated cisplatin-evoked nephrotoxicity by suppressing ROS-mediated activation of MAPK and NF-κB signaling pathways. Food Chem Toxicol 110:62–73. https://doi.org/10.1016/j.fct.2017.10.006 CrossRefPubMedGoogle Scholar
- Mercantepe T, Unal D, Tümkaya L, Yazici ZA (2018) Protective effects of amifostine, curcumin and caffeic acid phenethyl ester against cisplatin-induced testis tissue damage in rats. Exp Ther Med 15. https://doi.org/10.3892/etm.2018.5819
- Nematbakhsh M, Ebrahimian S, Tooyserkani M, Eshraghi-Jazi F, Talebi A, Ashrafi F (2013) Gender difference in cisplatin-induced nephrotoxicity in a rat model: greater intensity of damage in male than female. Nephrourol Mon 5:818–821. https://doi.org/10.5812/numonthly.10128 CrossRefPubMedPubMedCentralGoogle Scholar
- Ognjanović BI, Djordjević NZ, Matić MM, Obradović JM, Mladenović JM, Štajn AŠ, Saičić ZS (2012) Lipid peroxidative damage on cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium. Int J Mol Sci 13:1790–1803. https://doi.org/10.3390/ijms13021790 CrossRefPubMedPubMedCentralGoogle Scholar
- Pezeshki Z, Nematbakhsh M, Mazaheri S et al (2012) Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol 2012. https://doi.org/10.5402/2012/890310
- Rastghalam R, Nematbakhsh M, Bahadorani M, Eshraghi-Jazi F, Talebi A, Moeini M, Ashrafi F, Shirdavani S (2014) Angiotensin type-1 receptor blockade may not protect kidney against cisplatin-induced nephrotoxicity in rats. ISRN Nephrol 2014:1–7. https://doi.org/10.1155/2014/479645 CrossRefGoogle Scholar
- Sahin K, Orhan C, Tuzcu M, Muqbil I, Sahin N, Gencoglu H, Guler O, Padhye SB, Sarkar FH, Mohammad RM (2014) Comparative in vivo evaluations of curcumin and its analog difluorinated curcumin against cisplatin-induced nephrotoxicity. Biol Trace Elem Res 157:156–163. https://doi.org/10.1007/s12011-014-9886-x CrossRefPubMedGoogle Scholar
- Trujillo J, Molina-Jijón E, Medina-Campos ON, Rodríguez-Muñoz R, Reyes JL, Loredo ML, Barrera-Oviedo D, Pinzón E, Rodríguez-Rangel DS, Pedraza-Chaverri J (2016) Curcumin prevents cisplatin-induced decrease in the tight and adherens junctions: relation to oxidative stress. Food Funct 7:279–293. https://doi.org/10.1039/C5FO00624D CrossRefPubMedGoogle Scholar
- Uzunoglu S, Karagol H, Ozpuyan F, Cosar R, Cicin I, Yurutcaloglu V, Denizli B, Tanriverdi Ö, Sut N, Kocak Z (2011) Protective effect of l-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats. Med Oncol 28:690–696. https://doi.org/10.1007/s12032-010-9746-2 CrossRefGoogle Scholar
- Varatharajan R, Sattar MZA, Chung I, Abdulla MA, Kassim NM, Abdullah NA (2013) Antioxidant and pro-oxidant effects of oil palm (Elaeis guineensis) leaves extract in experimental diabetic nephropathy: a duration-dependent outcome. BMC Complement Altern Med 13:242. https://doi.org/10.1186/1472-6882-13-242 CrossRefPubMedPubMedCentralGoogle Scholar
- WHO (2008) World cancer report 2008. LyonGoogle Scholar